Turosteride

SKU: orb1737788

Description

Turosteride is a steroidal 5α-reductase inhibitor used in research for prostate cancer and other genitourinary disorders. Its antitumor activity has been investigated in both in vitro enzymatic assays and in vivo preclinical models of oncologic disease.

Research Area

Metabolism Research

Key Properties

• CAS Number: 137099-09-3
• MW: 459.66
• Purity: 99.85% (May vary between batches)
• Formula: C₂₇H₄₅N₃O₃
• SMILES: C[C@@]12[C@]([C@]3([C@@]([C@]4(C)[C@@](CC3)(N(C)C(=O)CC4)[H])(CC1)[H])[H])(CC[C@@H]2C(N(C(NC(C)C)=O)C(C)C)=O)[H]
• Target: Reductase
• Solubility: DMSO:45 mg/mL (97.9 mM)

Bioactivity

• In Vivo:
  Turosteride caused inhibition of rat and human prostatic enzymes, with IC50 values of 55 and 53 nM, respectively. In addition, turosteride did not show any relevant binding affinity to the rat prostate androgen receptor (IC50 84 μM; relative binding affinity 0.004% of DHT). The endocrine effects of turosteride were evaluated in adult male rats, treated orally at daily doses of 3, 10 and 30 mg/kg for 20 days. At these doses, the compound reduced the ventral prostate weight by 10, 33 and 42% and the intraprostatic total DHT content by 61, 74 and 78%, respectively, whereas no change in the intraprostatic content of T was observed. Turosteride caused a 40% reduction of serum DHT levels which, however, did not reach statistical significance, whereas serum T levels were similar to control animals. No effect on serum luteinizing hormone or prolactin was observed. These results indicate that the antiprostatic effect of turosteride in the adult rat is related to inhibition of the conversion of T to DHT.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

5-α reductase

Compound Identifiers

PubChem CID

65986